Laura Goff, M.D.
- Associate Professor of Medicine (Hematology/Oncology)
- Executive Medical Director for the VICC Cancer Patient Care Center
- Co-Chair, Data and Safety Monitoring Committee
Laura Goff, M.D.
- Associate Professor of Medicine (Hematology/Oncology)
- Executive Medical Director for the VICC Cancer Patient Care Center
- Co-Chair, Data and Safety Monitoring Committee
laura.goff@vumc.org
2220 Pierce Avenue
777 Preston Research Building
Nashville, TN 37232-6307
777 Preston Research Building
Nashville, TN 37232-6307
Research Program
Departments/Affiliations
Provider Information
Profile
Dr. Goff is a medical oncologist who specializes in gastrointestinal cancers with an emphasis on tumors of the liver and biliary tract. Dr. Goff received her medical degree from the University of Texas Health Science Center in San Antonio. She went on to complete a residency in Internal Medicine at the University of Texas Southwestern Medical Center at Dallas and then moved to Vanderbilt University for fellowship training in Hematology and Oncology. She joined the faculty in the GI Oncology program at Vanderbilt in 2007. Dr. Goff is interested in developing the use of new therapeutics in gastrointestinal malignancies through clinical trials and translational research.
Education
- Duke University, B.S., Chemistry, 1993-1997
- University of Texas Medical School at San Antonio, M.D., 1997-2001
- University of Texas Southwestern, House Officer, 2001-2004
- Fellow, Hematology/Oncology, Vanderbilt University Medical Center, 2004-2007
- Vanderbilt University, Master of Science in Clinical Investigation, 2006-2008
Research Emphasis
Research Description
Publications
- Chan E, Goff LW, Cardin DB, Ancell K, Smith SJ, Whisenant JG, Ye F, Berlin JD. Phase II study of the Multikinase inhibitor of angiogenesis, Linifanib, in patients with metastatic and refractory colorectal cancer expressing mutated KRAS. Invest New Drugs [print-electronic]. 2017 Aug; 35(4): 491-8. PMID: 28353122, PII: 10.1007/s10637-017-0458-8, DOI: 10.1007/s10637-017-0458-8, ISSN: 1573-0646.
- Cardin DB, Thota R, Goff LW, Berlin JD, Jones CM, Ayers GD, Whisenant JG, Chan E. A Phase II Study of Ganetespib as Second-line or Third-line Therapy for Metastatic Pancreatic Cancer. Am. J. Clin. Oncol [print-electronic]. 2017 Mar 3/15/2017; PMID: 28301350, DOI: 10.1097/COC.0000000000000377, ISSN: 1537-453X.
- Goff LW, Cardin DB, Whisenant JG, Du L, Koyama T, Dahlman KB, Salaria SN, Young RT, Ciombor KK, Gilbert J, Smith SJ, Chan E, Berlin J. A phase I trial investigating pulsatile erlotinib in combination with gemcitabine and oxaliplatin in advanced biliary tract cancers. Invest New Drugs [print-electronic]. 2017 Feb; 35(1): 95-104. PMID: 27853997, PMCID: PMC5306261, PII: 10.1007/s10637-016-0406-z, DOI: 10.1007/s10637-016-0406-z, ISSN: 1573-0646.
- Pauff JM, Goff LW. Current Progress in Immunotherapy for the Treatment of Biliary Cancers. J Gastrointest Cancer. 2016 Dec; 47(4): 351-7. PMID: 27538880, PII: 10.1007/s12029-016-9867-8, DOI: 10.1007/s12029-016-9867-8, ISSN: 1941-6636.
- Goff LW, Cohen RB, Berlin JD, de Braud FG, Lyshchik A, Noberasco C, Bertolini F, Carpentieri M, Stampino CG, Abbattista A, Wang E, Borghaei H. A Phase I Study of the Anti-Activin Receptor-Like Kinase 1 (ALK-1) Monoclonal Antibody PF-03446962 in Patients with Advanced Solid Tumors. Clin. Cancer Res [print-electronic]. 2016 May 5/1/2016; 22(9): 2146-54. PMID: 26655846, PII: 1078-0432.CCR-15-1622, DOI: 10.1158/1078-0432.CCR-15-1622, ISSN: 1078-0432.
- Chan E, Arlinghaus LR, Cardin DB, Goff L, Berlin JD, Parikh A, Abramson RG, Yankeelov TE, Hiebert S, Merchant N, Bhaskara S, Chakravarthy AB. Phase I trial of vorinostat added to chemoradiation with capecitabine in pancreatic cancer. Radiother Oncol [print-electronic]. 2016 May; 119(2): 312-8. PMID: 27106554, PMCID: PMC4961249, PII: S0167-8140(16)31047-7, DOI: 10.1016/j.radonc.2016.04.013, ISSN: 1879-0887.
- Katsha A, Belkhiri A, Goff L, El-Rifai W. Aurora kinase A in gastrointestinal cancers: time to target. Mol. Cancer. 2015 May 5/20/2015; 14: 106. PMID: 25987188, PMCID: PMC4436812, PII: 10.1186/s12943-015-0375-4, DOI: 10.1186/s12943-015-0375-4, ISSN: 1476-4598.
- Puzanov I, Lindsay CR, Goff L, Sosman J, Gilbert J, Berlin J, Poondru S, Simantov R, Gedrich R, Stephens A, Chan E, Evans TR. A phase I study of continuous oral dosing of OSI-906, a dual inhibitor of insulin-like growth factor-1 and insulin receptors, in patients with advanced solid tumors. Clin. Cancer Res [print-electronic]. 2015 Feb 2/15/2015; 21(4): 701-11. PMID: 25212606, PII: 1078-0432.CCR-14-0303, DOI: 10.1158/1078-0432.CCR-14-0303, ISSN: 1078-0432.
- Puzanov I, Sosman J, Santoro A, Saif MW, Goff L, Dy GK, Zucali P, Means-Powell JA, Ma WW, Simonelli M, Martell R, Chai F, Lamar M, Savage RE, Schwartz B, Adjei AA. Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors. Invest New Drugs [print-electronic]. 2015 Feb; 33(1): 159-68. PMID: 25294187, PMCID: PMC4295023, DOI: 10.1007/s10637-014-0167-5, ISSN: 1573-0646.
- Cardin DB, Goff L, Li CI, Shyr Y, Winkler C, DeVore R, Schlabach L, Holloway M, McClanahan P, Meyer K, Grigorieva J, Berlin J, Chan E. Phase II trial of sorafenib and erlotinib in advanced pancreatic cancer. Cancer Med [print-electronic]. 2014 Jun; 3(3): 572-9. PMID: 24574334, PMCID: PMC4101748, DOI: 10.1002/cam4.208, ISSN: 2045-7634.
- Johnson DB, Dahlman KH, Knol J, Gilbert J, Puzanov I, Means-Powell J, Balko JM, Lovly CM, Murphy BA, Goff LW, Abramson VG, Crispens MA, Mayer IA, Berlin JD, Horn L, Keedy VL, Reddy NM, Arteaga CL, Sosman JA, Pao W. Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel. Oncologist [print-electronic]. 2014 Jun; 19(6): 616-22. PMID: 24797823, PMCID: PMC4041676, PII: theoncologist.2014-0011, DOI: 10.1634/theoncologist.2014-0011, ISSN: 1549-490X.
